Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Busulfan

Review the clinical trials studying busulfan on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-45 of 45

Donor Stem Cell Transplant with Personalized Conditioning Regimens for the Treatment of Sickle Cell Disease and Other Transfusion Dependent Red Blood Cell Disorders
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
T Cell Receptor Alpha/Beta Depletion Peripheral Blood Stem Cell Transplantation for the Prevention of Graft Versus Host Disease in Children and Adults with Hematological Malignancies
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Reduced Intensity Conditioning Regimen for the Treatment of Non-Malignant Disorders
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Alpha/Beta T Cell Depleted Stem Cell Transplant in Treating Patients with Fanconi Anemia or Telomere Biology Disorder
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Personalized NK Cell Therapy after Chemotherapy and Cord Blood Transplant in Treating Patients with Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Modified Memory-Like NK Cells and TCRαβ T-cell Depleted Half-Matched Related Donor Transplant for the Treatment of High-Risk Acute Myeloid Leukemia (ABCD NK trial)
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
CD45RA Depleted T Cell Infusion after Alpha/Beta Depleted Stem Cell Transplant for the Reduction of Complications in Patients at Risk for Viral or Fungal Infections
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Donor Blood Stem Cells (Ex Vivo TCR Alpha/Beta and CD19-Depleted Stem Cells) for the Prevention of Graft-versus-Host Disease in Pediatric Patients with Blood Cancer
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Ruxolitinib with or without Abatacept for the Prevention of Graft Versus Host Disease and Cytokine Release Syndrome after T-cell Haploidentical Stem Cell Transplant in Patients with Hematologic Malignancies
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia
Status: Active
Location: See ClinicalTrials.gov
TCRalpha/beta and CD19+ depleted Hematopoietic Stem Cell Transplant from Closely Matched Unrelated Donors or Haploidentical Related donors for Blood Disorders in Children and Young Adults
Status: Approved
Location: 2 locations
Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate before Donor Stem Cell Transplant in Treating Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Venetoclax, Busulfan, Fludarabine, Azacitidine, Decitabine, and Cedazuridine in Treating Patients with High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndromes Undergoing Donor Stem Cell Transplantation
Status: Temporarily Closed to Accrual
Location: 2 locations
Itacitinib for the Prevention of Graft Versus Host Disease
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
MYELOMATCH: A Screening Study to Assign People with Myeloid Cancer to a Treatment Study or Standard of Care Treatment within myeloMATCH (MyeloMATCH Screening Trial)
Status: Active
Location: 310 locations
Immune Suppression Treatment for People With Sickle Cell Disease or Beta-Thalassemia Who are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Active
Location: 7 locations
Abatacept in Combination with Mycophenolate Mofetil and Tacrolimus for the Prevention of Graft-versus-Host Disease after Omidubicel Hematopoietic Cell Transplant
Status: Active
Location: Duke University Medical Center, Durham, North Carolina